Fresh off the press from the UK Court of Appeal is a decision concerning the pharmaceutical drug Xtandi (Enzalutamide). Xtandi is indicated in various oncology treatments in Australia and is listed at number 19 the of top 200 selling pharmaceuticals by retail in 2024. Keen-eyed medicinal chemists will notice that the previously published compound RD162 …
>> Read more
The emergence of protein degraders, including proteolysis-targeting chimeras (PROTACs) and molecular glues, represents one of the most exciting shifts in drug discovery over the past 20 years. By harnessing the body’s own protein disposal machinery, protein degraders can selectively remove disease-causing proteins, opening the door to treatments for previously ‘undruggable’ targets. Recent clinical milestones, such …
>> Read more
Trade mark owners and non-use removal applicants have been offered a reminder of the importance of considering any obstacles to the use of a trade mark by the decision in Thomas v Monsoon Group. The removal applicant who was successful before the Trade Mark Office did not contest the appeal, paving the way for the …
>> Read more
Australia’s life sciences ecosystem is experiencing sustained growth, driven by advances in biotechnology, digital health, precision medicine, agricultural innovation and materials science. While pharmaceuticals continue to dominate in terms of patent filings and regulatory complexity, the broader life sciences sector – encompassing agtech, medtech and next-generation materials such as semiconductors and battery technologies – is …
>> Read more
In the recent decision of Aqua HD [2025] APO 2, the Delegate denied a request for an extension of time made by a patent applicant’s trustee, who had been appointed by the court to wind down the company following insolvency proceedings. The Delegate concluded that the trustee failed to demonstrate that any force majeure events were causally linked to …
>> Read more
It is with great sadness that we advise that former Principal of POF, David Tadgell, passed away a few days ago. David joined Phillips Ormonde Fitzpatrick in 1983 and became a partner in 1993. David was a key member of the Chemistry & Life Sciences group at POF and served on our management committee and …
>> Read more
You might be tempted to ask Artificial Intelligence for legal advice. But as we’ve seen from the decision in Valu v Minister for Immigration it’s not a reliable source of information. In this case, an immigration lawyer used AI to assist in drafting legal submissions. The submissions were found to include references to cases and …
>> Read more
We have been made aware of scam emails regarding Trade Mark protection that appear to be sent by several POF Attorneys using incorrect and fraudulent email addresses. These emails from “Trademark Registry Hub” falsely claim to offer assistance and urge you to take immediate action to protect your intellectual property rights. This is a serious …
>> Read more
The United States Patent and Trademark Office (USPTO) has announced significant fee changes for US IP rights, effective from 18 January 2025. PatentsOn top of an increase of about 7.5% to most patent fees, significant increases and new fees have been introduced to incentivize efficient patent prosecution strategies and reduce the burden on patent examiners. …
>> Read more
This year, Phillips Ormonde Fitzpatrick (POF) proudly marks our 30th anniversary in the Sydney office. This milestone provides an opportunity to reflect on POF’s growth and to recognise where we are today. “Our Sydney office opened in Chatswood in 1994 following ever-increasing demand from our Sydney and NSW-based clients. We are very pleased that our …
>> Read more
